Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 10Lung Neoplasms 3Neuroblastoma 2Recurrence 1Non-Small Cell Lung Cancer ALK-positive 1Non Small Cell Lung Cancer Metastatic 1Neoplasm Metastasis 1Meningeal Carcinomatosis 1Glioma 1Glioblastoma 1Ganglioneuroblastoma 1Diffuse Intrinsic Pontine Glioma 1Carcinoma 1Brain Neoplasms 1Astrocytoma 1Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer 1Advanced Non-Small Cell Lung Cancer 1ALK Positive Non-small Cell Lung Cancer 1

Interventions

Temozolomide 6Radiotherapy 4Cyclophosphamide 3TIC10 compound 2Specimen Handling 2Irinotecan 2Granulocyte-Macrophage Colony-Stimulating Factor 2Everolimus 2Etoposide 2Diphtheria-Tetanus Vaccine 2tovorafenib 1spartalizumab 1ribociclib 1pembrolizumab 1lutetium Lu 177 dotatate 1lorlatinib 1larotrectinib 1gallium maltolate 1fimepinostat 1etoposide phosphate 1dostarlimab 1dipinacoline glutamate 1dinutuximab 1balstilimab 1antineoplaston AS 2-1 1antineoplaston A10 1abemaciclib 1Vaccines 1Topotecan 1Standard of Care 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Diffuse Intrinsic Pontine Glioma × lorlatinib × 1 year × Clear all
NCT06333899 2026-03-12

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

Nationwide Children's Hospital

Phase EARLY_PHASE1 Recruiting
15 enrolled
CNS

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡